Related Experiment Video
Updated: May 3, 2026
MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
Published on: November 30, 2013
MicroRNA-29b inhibits diabetic nephropathy in db/db mice
Hai-Yong Chen1, Xiang Zhong1, Xiao R Huang2
1Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Abstract:
Inflammation and its consequent fibrosis are two main features of diabetic nephropathy (DN), but target therapy on these processes for DN remains yet ineffective. We report here that miR-29b is a novel therapeutic agent capable of inhibiting progressive renal inflammation and fibrosis in type 2 diabetes in db/db mice. Under diabetic conditions, miR-29b was largely downregulated in response to advanced glycation end (AGE) product, which was associated with upregulation of collagen matrix in mesangial cells via the transforming growth factor-β (TGF-β)/Smad3-dependent mechanism. These pathological changes were reversed by overexpressing miR-29b, but enhanced by knocking-down miR-29b. Similarly, loss of renal miR-29b was associated with progressive diabetic kidney injury, including microalbuminuria, renal fibrosis, and inflammation. Restored renal miR-29b by the ultrasound-based gene therapy was capable of attenuating diabetic kidney disease. Further studies revealed that inhibition of Sp1 expression, TGF-β/Smad3-dependent renal fibrosis, NF-κB-driven renal inflammation, and T-bet/Th1-mediated immune response may be mechanisms associated with miR-29b treatment in db/db mice. In conclusion, miR-29b may play a protective role in diabetic kidney disease and may have therapeutic potential for diabetic kidney complication.
Insights
MicroRNA-29b (miR-29b) shows promise for treating diabetic kidney disease. Restoring miR-29b levels in mice with type 2 diabetes reduced kidney inflammation and fibrosis, suggesting therapeutic potential.
Area of Science:
- Nephrology
- Molecular Biology
- Genetics
Background:
- Diabetic nephropathy (DN) is characterized by inflammation and fibrosis, with limited therapeutic options.
- Advanced glycation end (AGE) products downregulate miR-29b under diabetic conditions.
- Downregulation of miR-29b is linked to collagen matrix upregulation in mesangial cells via the TGF-β/Smad3 pathway.
Purpose of the Study:
- To investigate the therapeutic potential of miR-29b in inhibiting renal inflammation and fibrosis in diabetic nephropathy.
- To elucidate the mechanisms underlying miR-29b's protective effects in a mouse model of type 2 diabetes.
Main Methods:
- Utilized db/db mice, a model for type 2 diabetes.
- Manipulated miR-29b levels through overexpression and knockdown.
- Employed ultrasound-based gene therapy to restore renal miR-29b.
- Assessed pathological changes including microalbuminuria, fibrosis, and inflammation.
- Investigated the involvement of Sp1, TGF-β/Smad3, NF-κB, and T-bet/Th1 pathways.
Main Results:
- Diabetic conditions led to decreased miR-29b and increased renal fibrosis and inflammation.
- Overexpression of miR-29b reversed these pathological changes, while knockdown exacerbated them.
- Ultrasound-mediated restoration of miR-29b attenuated diabetic kidney disease progression.
- miR-29b treatment inhibited Sp1 expression, TGF-β/Smad3-dependent fibrosis, NF-κB-driven inflammation, and T-bet/Th1 immune responses.
Conclusions:
- miR-29b plays a protective role in diabetic kidney disease.
- Restoring miR-29b levels is a potential therapeutic strategy for diabetic kidney complications.
- The therapeutic effects involve the inhibition of key fibrotic, inflammatory, and immune pathways.
More Related Videos
07:01Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
06:48Quantitative Real-Time Polymerase Chain Reaction Evaluation of MicroRNA Expression in Kidney and Serum of Mice with Age-Dependent Renal Impairment
Published on: April 29, 2022
